open access
Pembrolizumab-induced diabetes


- Specialist Registrar in Endocrinology and Diabetes, King’s College Hospital NHS Foundation Trust, London, United Kingdom
- Consultant in Diabetes and Endocrinology, Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom
open access
Abstract
Not required for Clinical Vignette.
Abstract
Not required for Clinical Vignette.
Keywords
pembrolizumab; diabetes; diabetic ketoacidosis; malignant melanoma; check-point inhibitors


Title
Pembrolizumab-induced diabetes
Journal
Issue
Article type
Clinical vignette
Pages
414-415
Published online
2021-05-31
Page views
973
Article views/downloads
522
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2021;72(4):414-415.
Keywords
pembrolizumab
diabetes
diabetic ketoacidosis
malignant melanoma
check-point inhibitors
Authors
Rumaisa Banatwalla
Omar Zuhair Kirresh
Fahad Wali Ahmed


- Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One. 2016; 11(7): e0160221.
- Ishida M, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002; 84(1): 57–62.
- Colli ML, Hill JLE, Marroquí L, et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction. EBioMedicine. 2018; 36: 367–375.
- Clotman K, Janssens K, Specenier P, et al. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018; 103(9): 3144–3154.
- Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018; 67(8): 1471–1480.
- Eshet Y, Baruch EN, Shapira-Frommer R, et al. Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study. Cancer Immunol Res. 2018; 6(12): 1453–1458.